<DOC>
	<DOC>NCT01736475</DOC>
	<brief_summary>To assess efficacy and safety, including immunogenicity of BAX 855 administered as prophylaxis and as on-demand therapy in adult and adolescent (12-65 years) previously treated patients (PTPs) with severe hemophilia A To determine the pharmacokinetic (PK) parameters of BAX 855.</brief_summary>
	<brief_title>Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Main Participant and/or legal representative has/have voluntarily provided signed informed consent Participant is 12 to 65 years old at the time of screening Participant is male with severe hemophilia A (Factor VIII (FVIII) clotting activity &lt; 1%) as confirmed by central laboratory at screening after the appropriate washout period or a documented FVIII clotting activity &lt;1% Participant has been previously treated with plasmaderived FVIII concentrates or recombinant FVIII for ≥150 documented exposure days (EDs) Participant is currently receiving prophylaxis or ondemand therapy with FVIII Participant is willing and able to comply with the requirements of the protocol Main Participant has detectable FVIII inhibitory antibodies (≥ 0.6 Bethesda Units (BU) using the Nijmegen modification of the Bethesda assay) as confirmed by central laboratory at screening Participant has history of FVIII inhibitory antibodies (≥ 0.4 BU using the Nijmegen modification of the Bethesda assay or ≥ 0.6 BU using the Bethesda assay) at any time prior to screening Participant has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (eg, qualitative platelet defect or von Willebrand's disease).</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>